Previous 10 | Next 10 |
Pivotal Trials CARDINAL and MOXIe Fully Enrolled and Data Expected in the Second Half of 2019 FALCON Pivotal Phase 3 Trial to Initiate in May 2019 Conference Call With Management Scheduled for Today, May 9, 2019 IRVING, Texas, May 09, 2019 (GLOBE NEWSWIRE) ...
The following slide deck was published by Reata Pharmaceuticals, Inc. in conjunction with this Read more ...
IRVING, Texas, May 02, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that Colin Meyer, M.D., Reata’s Chief Medical Officer, will present a talk entitled “Translating the Novel Anti-Inflammatory ...
IRVING, Texas, May 02, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on recent progress on its development programs on Thursday, May 9 th , 2019 at ...
Most developers of therapies to treat nonalcoholic steatohepatitis (NASH) are under modest pressure as investors remain unimpressed with the initial announcements from The International Liver Congress in Vienna. More news on: Intercept Pharmaceuticals, Inc., Gilead Sciences, Inc., Enanta P...
Gainers: PLAY +7.6% . OTCQB:HLIX +3.8% . EVC +2.8% . PTGX +2.3% . ODT +2.1% . More news on: Dave & Buster's Entertainment, Inc., Helix TCS, Inc., Entravision Communications Corporation, Stocks on the move, Read more ...
Reata Pharmaceuticals, Inc. (RETA) Q4 2018 Results Earnings Conference Call February 27, 2019 08:00 PM ET Company Participants Vinny Jindal - VP, Strategy Warren Huff - CEO Colin Meyer - CMO Jason Wilson - CFO Conference Call Participants Yigal Nochomovitz - Citigroup ...
Reata Pharmaceuticals (NASDAQ: RETA ): Q4 GAAP EPS of -$0.86 beats by $0.21 . More news on: Reata Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, Read more ...
PIVOTAL TRIALS CARDINAL AND MOXIE FULLY ENROLLED WITH DATA EXPECTED SECOND HALF 2019 FALCON PIVOTAL PHASE 3 TRIAL TO INITIATE IN MID-2019 CONFERENCE CALL WITH MANAGEMENT SCHEDULED FOR TODAY, FEBRUARY 28, 2019 IRVING, Texas, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Reata Pharmace...
IRVING, Texas, Feb. 21, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage biopharmaceutical company, today announced that it will report financial results and provide an update on recent progress on its development programs on Thursday, February 28 th , 2...
News, Short Squeeze, Breakout and More Instantly...
Reata Pharmaceuticals Inc. Company Name:
RETA Stock Symbol:
NASDAQ Market:
Reata Pharmaceuticals Inc. Website:
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2...
Laser Photonics Corporation (LASE) is expected to report for Q2 2024 QuickLogic Corporation (QUIK) is expected to report $0.08 for Q3 2023 Stryve Foods Inc. (SNAX) is expected to report $-1.65 for Q3 2023 Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023 V...
Reata Pharmaceuticals Inc. (RETA) is expected to report $-2.15 for Q3 2023